N4 Pharma Plc (N4P.L) LSE
0.48
+0(+0.00%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
0.48
+0(+0.00%)
Currency In GBp
Address
60 Gracechurch Street
London, EC3V 0HR
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 1332 690061
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
5
First IPO Date
July 01, 1988
| Name | Title | Pay | Year Born |
| Nigel James Theobald | Founder, Chief Executive Officer & Executive Director | 82,500 | 1964 |
| David Horn Solomon | CEO & Director | 0 | 1960 |
| Luke Sebastian Cairns | Executive Director | 44,000 | 1978 |
| Andrew Leishman | Consultant | 0 | N/A |
| Fiona McLaughlin | Head of Research & Development | 0 | 1970 |
| Margaret Courtney | Head of Chemistry, Manufacturing & Controls | 0 | N/A |
| Mark Edbrooke | Head of Strategy | 0 | N/A |
| Rob Harris | Head of CMC Development | 0 | N/A |
N4 Pharma Plc, a specialist pharmaceutical company, develops novel silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.